Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
TD Cowen Upgrades RXO to Hold From Sell, Price Target is $30.25

TD Cowen Upgrades RXO to Hold From Sell, Price Target is $30.25

MT newswireMT newswire2026/10/07 11:24

07:24 AM EDT, 10/07/2026 (MT Newswires) -- RXO (RXO) has an average rating of hold and mean price target of $26.83, according to analysts polled by FactSet. (MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www.mtnewswires.com/contact-us)

07:24 AM EDT, 10/07/2026 (MT Newswires) -- RXO (RXO) has an average rating of hold and mean price target of $26.83, according to analysts polled by FactSet. (MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www.mtnewswires.com/contact-us)
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

The "chip dollar" is on the rise! Deutsche Bank: Asia's chip trade surplus flows into US stocks, becoming a new pillar for the dollar

Deutsche Bank believes that the continuously expanding chip trade surplus in Asia is becoming a supporting force for the US dollar, as related profits are increasingly being reinvested into the US stock market.

智通财经•2026/11/16 23:03
The "chip dollar" is on the rise! Deutsche Bank: Asia's chip trade surplus flows into US stocks, becoming a new pillar for the dollar

Roche's (RHHBY.US) new breast cancer drug Wilserdly approved by FDA: Analysts predict peak annual sales could reach up to $14.5 billion

Roche's (RHHBY.US) new oral breast cancer drug has been approved by U.S. regulators, paving the way for this medication, which the pharmaceutical company hopes will transform the treatment of the disease.

智通财经•2026/11/16 22:53